0001104659-21-110547.txt : 20210827 0001104659-21-110547.hdr.sgml : 20210827 20210827161532 ACCESSION NUMBER: 0001104659-21-110547 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210826 FILED AS OF DATE: 20210827 DATE AS OF CHANGE: 20210827 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Niklason Laura E CENTRAL INDEX KEY: 0001878075 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39532 FILM NUMBER: 211219082 MAIL ADDRESS: STREET 1: 35 WILSHIRE ROAD CITY: GREENWICH STATE: CT ZIP: 06831 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Humacyte, Inc. CENTRAL INDEX KEY: 0001818382 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 851763759 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2525 EAST NORTH CAROLINA HIGHWAY 54 CITY: DURHAM STATE: NC ZIP: 27713 BUSINESS PHONE: 919-313-9633 MAIL ADDRESS: STREET 1: 2525 EAST NORTH CAROLINA HIGHWAY 54 CITY: DURHAM STATE: NC ZIP: 27713 FORMER COMPANY: FORMER CONFORMED NAME: Alpha Healthcare Acquisition Corp. DATE OF NAME CHANGE: 20200716 4 1 tm2125954-26_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2021-08-26 0 0001818382 Humacyte, Inc. HUMA 0001878075 Niklason Laura E 2525 EAST NORTH CAROLINA HIGHWAY 54 DURHAM NC 27713 1 1 1 0 President, CEO and Director Common Stock 2021-08-26 4 A 0 1148240 A 1148240 D Common Stock 2021-08-26 4 A 0 18930004 A 18930004 I By Ayabudge LLC Common Stock 2021-08-26 4 P 0 1522500 10.00 A 20452504 I By Ayabudge LLC Common Stock 810161 I By Spouse Stock Options (right to buy) 1.19 2021-08-26 4 A 0 262596 A 2023-11-22 Common Stock 262596 262596 D Stock Options (right to buy) 2.56 2021-08-26 4 A 0 13129 A 2025-09-01 Common Stock 13129 13129 D Stock Options (right to buy) 2.56 2021-08-26 4 A 0 157558 A 2026-03-09 Common Stock 157558 157558 D Stock Options (right to buy) 3.44 2021-08-26 4 A 0 262596 A 2026-09-14 Common Stock 262596 262596 D Stock Options (right to buy) 6.54 2021-08-26 4 A 0 131298 A 2028-04-12 Common Stock 131298 131298 D Stock Options (right to buy) 10.28 2021-08-26 4 A 0 1312984 A 2021-11-09 2031-01-14 Common Stock 1312984 1312984 D Stock Options (right to buy) 10.28 2021-08-26 4 A 0 1575 A 2021-12-14 2030-12-14 Common Stock 1575 1575 D Stock Options (right to buy) 2.56 2021-08-26 4 A 0 13129 A 2025-09-01 Common Stock 13129 13129 I By Spouse Stock Options (right to buy) 6.54 2021-08-26 4 A 0 17068 A 2028-04-12 Common Stock 17068 17068 I By Spouse On August 26, 2021 , Alpha Healthcare Acquisition Corp. ("AHAC") consummated a business combination (the "Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub") and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each share of Legacy Humacyte stock was exchanged for 0.2626 shares of common stock of Humacyte, Inc. Options are fully vested and exercisable. As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. One-third of the option will vest on each of the three anniversaries after November 9, 2020. Options to purchase 2,625 shares of Common Stock granted on 12/14/2020, which vest as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Accordingly, columns 5, 7, and 9 of Table II report the number of securities equal to three-fifths of the 12/14/2020 option grant. /s/ Laura E. Niklason by Dale A. Sander as Attorney-in-Fact 2021-08-27